WindMIL Therapeutics
1812 Ashland Avenue, 1st Floor
Suite 100
Baltimore
Maryland
21205
United States
Tel: 410-558-1906
Website: https://windmiltherapeutics.com/
About WindMIL Therapeutics
When it comes to cell therapy – cell source matters. At WindMIL, we are harnessing the power of bone marrow derived lymphocytes (MILs) to develop ground-breaking immunotherapies to treat cancer patients. The bone marrow is a natural reservoir of T cells with unique advantages including inherent tumor-specificity. We have perfected an efficient and rapid process to extract, activate and expand MILs for future commercial applications. Our lead program is in a large Phase 2b study in high-risk multiple myeloma with additional programs in solid tumors using MILs advancing to the clinic. We are also advancing programs to supercharge MILs through genetic-modification.
YEAR FOUNDED:
2015
LEADERSHIP:
Founders: Ivan Borrello, MD and Kimberly Noonan, PhD
CEO: Brian Halak, PhD
CMO: Dr. Steven Fischkoff
CSO: Kimberly Noonan, PhD
TECHNOLOGY
Please click here for WindMIL's technology.
4 articles with WindMIL Therapeutics
-
WindMIL Therapeutics and University of Michigan Announce Collaboration to Collect Bone Marrow from Patients with Head and Neck Cancer to Develop Marrow Infiltrating Lymphocytes (MILs™)
7/9/2019
WindMIL Therapeutics and the University of Michigan Rogel Cancer Center today announced that the first patients have been identified in an investigator-sponsored study for the collection of bone marrow from patients with head and neck squamous cell carcinoma.
-
WindMIL Therapeutics Announces $32.5 Million in Series B Financing
6/18/2018
Phase 2, multi-center randomized trial of MILs™ in high-risk multiple myeloma fully enrolled
-
WindMIL Therapeutics, based in Baltimore, Maryland, filed a form D with the U.S. Securities and Exchange Commission, indicating it had raised $32.53 million in equity financing.
-
WindMIL Therapeutics Announces New Cancer Immunotherapy Approach Based On Marrow-Infiltrating Lymphocytes
10/5/2017